Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
28.71
-0.17 (-0.59%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
33
34
Next >
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
November 01, 2022
From
Pfizer Inc.
Via
Business Wire
Why Investors Are Suddenly Excited About Vaxcyte
October 31, 2022
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
Via
MarketBeat
Exposures
COVID-19
Author A. D. Stowers' New Book 'Michaela's Miracle' is a Stirring True Story of Loss, Heartache and Joy Centered Around a Young Woman Who Comes to Understand Love
October 28, 2022
Recent release 'Michaela's Miracle' from Covenant Books author A. D. Stowers is an impactful tale based on true events that follow Michaela, who has only ever known rejection and abandonment her entire...
Via
Newswire.com
Pfizer Stock Falls After a Tax Investigation Is Launched Against the Company in Italy
October 27, 2022
Pfizer Stock (NYSE:PFE) According to a story published on Thursday by Reuters, which cited two individuals with knowledge of the situation, the tax authorities in Italy are probing the earnings...
Via
PressReach
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Pfizer Inc. (PFE) on Behalf of Investors
October 27, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Pfizer Inc. and Encourages Investors with Losses to Contact the Firm
October 27, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Pfizer Inc. (PFE) on Behalf of Investors
October 27, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
October 27, 2022
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all...
Via
MarketBeat
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pfizer Inc. and Encourages Investors with Losses to Contact the Firm
October 26, 2022
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Pfizer Inc. (PFE) on Behalf of Investors
October 26, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
October 20, 2022
From
Erasca, Inc.
Via
GlobeNewswire
Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022
October 18, 2022
From
Pfizer Inc.
Via
Business Wire
MarketBeat: Week in Review 10/10-10/14
October 15, 2022
A volatile week is ending with the market moving lower. Here are some of the stories the MarketBeat analysts were covering this week.
Via
MarketBeat
Exposures
COVID-19
Pharma Trend Honors the Best Pharmaceutical Companies and the Most Innovative Products 2022
October 14, 2022
Via
Magic PR
Exposures
COVID-19
Global Antivenom Market Size to Surpass US$ 1057.6 Million by 2027
October 13, 2022
Global Antivenom Market Report, History and Forecast 2016-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application
Via
SBWire
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
October 13, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
October 12, 2022
From
Pfizer Inc.
Via
Business Wire
Is Pfizer Stock Still Worth Buying After the Pandemic?
October 12, 2022
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.
Via
MarketBeat
Exposures
COVID-19
CAPEX.com Launches Share Dealing and ETF Trading Product - CAPEX Invest
October 05, 2022
Bucharest, Romania--(Newsfile Corp. - October 5, 2022) - After previously announcing a zero-commission pre-launch campaign for share dealing, CAPEX.com unveils...
Via
Newsfile
Topics
ETFs
Pfizer Completes Acquisition of Global Blood Therapeutics
October 05, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
October 04, 2022
From
Pfizer Inc.
Via
Business Wire
CFund Capital to Present at Blockchain Expo North America October 5-6
October 03, 2022
Markham, ON () October 3, 2022 -- CFund is a professional platform integrating investor education, liquidity provision and crypto asset management.
Via
Prodigy
Topics
Economy
Exposures
Supply Chain
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
October 03, 2022
From
Pfizer Inc.
Via
Business Wire
The Road to Health never ends
September 27, 2022
Via
eTrendy Stock
Exposures
COVID-19
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
September 26, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer Declares Fourth-Quarter 2022 Dividend
September 22, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries
September 22, 2022
From
Pfizer Inc.
Via
Business Wire
Novavax Remains a Risk-On Stock in a Risk-Off Market
September 22, 2022
NVAX is a risk-on stock at a time investors are turning to risk-off assets. This article looks to see if Novavax still presents an opportunity for investors
Via
MarketBeat
Topics
Earnings
Exposures
Financial
Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts
September 20, 2022
From
Pfizer Inc.
Via
Business Wire
Hematological Malignancies Market size is estimated to reach $106.4 billion by 2027 – IndustryARC
September 19, 2022
Continue reading "Hematological Malignancies Market size is estimated to reach $106.4 billion by 2027 – IndustryARC"
Via
Get News
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.